A new family of compounds slows the progression of Parkinson’s disease by slamming the door on calcium. Parkinson’s, the second most common neurodegenerative disease, is caused by the death of dopamine neurons, resulting in tremors, rigidity, and difficulty moving. Current treatments target the symptoms but do not slow the progression of the disease.
